Note: Descriptions are shown in the official language in which they were submitted.
~ ~t7~ 3~
METHOD FOR ENHANCING AND/OR ACCELERATING IMMUNOASSAY
DETECTION OF HUMAN CARCINOMA TUMOR ASSOCIATED
ANTIGEN IN A PATHOLOGY SAMPL~
This invention relates generally to immunoassay
detectlon o~ human carcinoma tumors by means of a
labelled murine monoclonal antibody demonstrating reac-
tivity to a speciflc antigen on the surface of human
carcinoma cells and ti~sues, and more particularly, to
a unique immunoassay method lnvolving removal Or a car-
bohydrate steric hindrance for such monoclonal antibody
availability to bind the antigen for which it is
specific.
The total immune system of a human includes an
adaptive immune system whose ~unction is to produce a
specific reaction ko an infectious disease which will
enable recovery from the disease. In thls function,
the adaptive immune system is called upon to evolve
molecules called antibodiesO Antibodies are molecules
produced by B lymphocytes having antigen binding por-
tions which can recognize a determlnant or antigenic
site of the infectious disease or on dlseased cells. A
- particular antibody molecule can bind only to one type
of infectious disease or diseased cell or tissue. Fur-
ther, each antibody molecule binds to only one of the
many molecules on the disease mlcroorganism's or dis-
eased cell's surface. Those molecules to which anti-
bodies blnd are known as antigens.
It is known that different antibodies will bind to
different antigens wlth each antlbody being specific
for a particular antigen. Any particular antigen
molecule can have several di~ferent determinant sites
or epitopes or may have ~everal identical epitopes.
Thus, antlbodies really are specific for the epitopes
or determinant antigenlc sites rather than the whole
antigen molecule. Thus, each antlbody molecule effec-
tively recognizes one epitope rather than the whole
antigen.
. ,~
. . .
.: .
, ,.. .~".. . , -
,, .~ ~.., :: :,.
~ ~7 [)~94
~2--
There has been ldenti~led a murine monoclonal
antibody whlch ~ speclflc for a unlque antigenic
determinant or epitope of a human carclnoma tumor cell.
The antigen is called the "KC-4 antlgen" and the
monoclonal antlbody ls called "KC-4". The antlgen
molecule has been isolated and identlfied as having two
forms. The larger form has an approximate molecular
weight of 490,000 daltons (range of 480,000 to
510,000), and occurs only in the cytoplasm o~ the car-
cinoma cells. The smaller form has an approximatemolecular welght of 438~000 daltons (range of 390,000
to 450,000) and occurs both in the cytoplasm and mem-
brane of carcinoma cells. A sample of both hybrid cell
llnes capable Or produclng monoclonal antibodies
speclfic for this antlgen are on deposit wlth the
American Type Culture Collection and are assigned the
Nos. llB 8709 (IgG3) and HB 8710 (IgM).
This KC-4 monoclonal antibody is available commer-
clally from the Coulter Immunology Division of Coulter
Corporation, Hialeah, ~lorlda ln a solid tumor marker
klt under the regi~tered trademark COU~TER CLONE~.
Thls ls a carcinoma marker immunoperoxldase kit whlch
is com~lete for routine use with tissues ~uch as
breast, lung, prostate, stomach and colon in the lnves
tlgation of adenocarcinoma and squamous cell carclnoma.
The kit can be applied to single cell suspensions ~cell
lines), frozen sections and paraffin embedded tissues.
The immunoa~say kit is avallable for research use to
identify solid tumor markers in neoplastlc tissue~ The
KC-4 monoclonal antibody has been available for diag-
nostic detectlon o~ carclnoma markers by researchers
using other immunoassay techniques, including rlow
cytometric technlques or where the KC-Ii monoclonal
antibody is coated on a substrate or support member
such as a microsphere for binding to the KC-4 antlgen.
. . . . .
.. : . ..
. ~. . ,- .-
-: ~
': : :, :
31 ;~7~3~
Thus, achleving meanlngful dlagnoætlc detectlon of
the KC-4 antlgen ln a pathologlcal cell saMple using
routlne or conventlonal immunoassay technlques is
known. There have been descrlbed numerous lmmunoassay
techniques for detecting the binding of the KC-4
monoclonal antlbody to the KC 4 antigen on the membrane
or surface of a pathologlcal sample. In each case, the
reactlve blnding of a stalned or labelled KC-4
monoclonal antibody to the determlnant slte or epltope
of the antigen will slgnal lts detectlon. Obvlously
critlcal to such detection procedures in a pathological
sample ls adequate monoclonal antibody availability to
blnd the determinant site of the antigen for which it
ls speclflc. This presumes that the antigenic
determinant is freely available without hlndrance to
bindlng with lts specific monoclonal antibody at all
stages of development of the human carclnoma cells, in-
cluding ln the very early stages of carcinoma cell de-
velopment. Thus, percentage of positive carclnoma cell
detection is important. Also important is being able
to detect such CanGer at its very early development
~ stage where the percentage of positive antigen detec-
tion may be quite small~
Applicant has determined that khere is a car-
bohydrate steric hindrance to bindlng of the KC-4 mono-
clonal antibody to the smaller form of KC-4 antigen on
the surface or membrane of the carcinoma cell by reason
of sialic acid resldue on the KC-4 antigen. The ex-
presslon of the KC-4 antigen on the surface of the car-
cinoma cell was found to be directly related to thesialic acid on the KC-4 antigen. ~y removal of the
sialic acid on the XC-4 antlgen of the tumor cell, ap-
plicant has been able to enhance and/or accelerate
detection, as by staining or labelling of the KC-4
antigen, which was not detectable by conventional or
routine in vitro lmmunoassay techniques~ By removing
....
.,: ,, :. .
..
~: ~"' ' ' ' ' '
,:
~'7~l9~
the determlned carbohydrate steric hindrance on the
identiried KC 4 antigen, appllcant has been able to in-
crease the ability to detect human carclnoma tumors in
a pathology sample by at least a factor o~ two (2).
The method of the invention enhances the percentages of
pathological cells detectable and even provides ~or
earlier detectlon of solid tumor cells than heretofore
achieved by routine immunoassay techniques.
Accordlngly, the invention provides an immunoa~say
method for detectlng a human carclnoma assoclated
antlgen ln a pathology sample, said method character-
ized by the steps of treatlng a carclnoma cell sample
prepared for assay with an enzyme selected to dlge~t a
carbohydrate residue affixed to antigenlc siteff on the
membrane of the cells of the sample and expose the
same; and contacting the cells with a labelled mono-
clonal antibody specific to sald antigenlc sites to
produce detectable labelled complexes.
Further, the inventlon provides an lmmunoassay
testing klt for carcinoma marking of neoplastic tlssue
to locate and identify solid tumor cells involvlng
breast, colon, lung, stomach and prostate3 said klt in-
cluding, the monoclonal antibody antl-KC-4 specific ~or
bindlng to the determinant site of the KC-4 antigen on
the membrane of the tumor cell; a reagent label ~or the
monoclonal antibody; and an enzyme for digestlng a car-
bohydrate ~ugar residue attached to the KC-4 antigen
which hinders availability of the KC-4 monoclonal
antibody to bind to the KC-4 antigen.
The method embodylng the invention is directed to
enhancing and/or acceleratlng the percentage of posi-
tive carcinoma cell detection in a pathological sample.
Multiple tests were conducted employing the inventlon
method as explalned hereinafter.
Individual frozen sections of lung carcinoma tlssue
and breast carclnoma tissue were tested. Also, frozen
,,:.
~: : --. -- :
:: , . ' ' : ` '
~o~
-5
sections Or normal lung and breast tlssue were tested.
The monoclonal antlbody KC-4 was used at a selected
dllutlonO Pathology samples were prepared for mlcro-
scoplc analysls to enable labelling or stalnlng with
KC-4 antlbody on one set of sample slides in a routine
or conventional manner and on a second set of sample
slldes using the method Or this lnvention. A thlrd set
of slldes was prepared to provlde normal tlssue in the
testing procedures. A plurallty of the dlfferent sets
of pathology samples and normal tlssue samples were
prepared so as to enable testlng under varying condi-
tlons as explalned hereln.
The sets of pathology and normal tissue sample
slldes inltlally were treated wlth the labelled XC-4
monoclonal antlbody. Then, the second set of slides
were treated wlth a wash of the en~yme neuramlnidase. -
Then~ the sets of sllde samples were selectively in-
cubated for thirty to slxty minute periods at a
temperature of approximately 37 Celsius. Thus, the
dlfferent slide sample sets were lncubated for diP-
ferent periods of tlme wlth results monitored for each
of the slide sample sets at the di~ferent incubation
periods established~
The results of these test procedures were as
~ollows:
1. No stainlng activlty was dlscerned in any of
the ~lide sample sets uslng normal tissue~ m e KC-4
monoclonal antlbody dld not blnd to normal tissue.
2. The ~lide sample sets sub~ected to enzyme di-
gestlon using neuraminidase exhlblted brighter staindlscernment and a greater percentage of positlve cell
stainlng than the sllde sample set which was not
treated wlth neuramlnidase.
3. Sub~ectlng the neuramlnidase treated slide
sample sets to longer lncubation periods revealed ln-
creased staining of the neoplastic tissue. There was
: ' .` ' ': ' ' -
..,
~7~3~9~
an indlcatlon of some de~truction of tlssue architec-
ture at the longer lncubatlon periods.
4. Incubation at room temperature appeared
preferable. Tests were repeated uslng lr~unoperoxidase
stalnlng wlth KC-4 monoclonal antlbody and tissue sec-
tions of colon cancer, llver canc-er, prostate cancer,
breast cancer, lung cancer, both frozen and paraffln
flxed. Sllde sample sets were treated wlth
neuraminidase and incubated as previously described
along wlth sample slide sets which dld not undergo
neuraminidase enzyme digestion~ The results estab-
lished that neur mlnldase treated pathology samples,
both frozen and paraffin flxed, stained darker than
routlnely treated cancer samples. Thls indicated a
greater percentage of positlve cancer cell detection
usinq said neur~Nnidase trea~nt.
A further series of tests were conducted ln whlch
lung and llver sample cancer tlssues were treated with
neuraminldase and correspondlng tlssue samples were
treated routinely, i.e~, wlthout neuraminidase. The
KC-4 monoclonal antibody was used ln each instance and
a sultable lncubatlon period at proper temperature was
run wlth the following results:
1. In the case of the lung tissue sample treated
with neuramlnidase, the staining color was deeper and
the percentage of positive cells detected was 37%. In
the case of the non-neuraminldase treated sample/ the
percentage of positive cells detected was 19%.
2. In the case of liver tissue samples, the
neuraminldase treated sample evldenced dark brown
staining in the ma~ority of large cells which were
granular ln appearance. The non-neur~minldase treated
llver tissue samples evidenced only faint stalnlng in
some larger cells which appeared granular also.
Appllcant belleves that the phenomena described
herein bears a direct relationship to the structural
- ~ .. ' :
,
7~
--7
and functlonal nature Or the proteins formlng the mem-
brane of the tumor cell. Glycoproteins are integral
components Or cell membranes. In the case of carclnoma
tumor cells, such glycoprotelns have a transmembrane
reglon on the surface of the membrane to whlch sugar
residues, such as sialic acid, can attach. Appllcant
belleves that slallc acid molecules attach to the KC-4
anti~en exposed on the membrane of human carclnoma
tumor cells so as to mask this determinant site and
prevent its belng recognlzed by the KC-4 monoclonal
antibody which does not bind to normal tissue. This ls
asserted because the carbohydrate sialic acid ls known
to be located on the exterior of a cell membrane only.
When this carbohydrate is enzyme dl~ested by
neuramlnldase, the KC-4 antigen becomes available f`or
binding to the KC-monoclonal antibody and ls detected
more promlnently as established by the test results
recited.
Applleant has provided a method for immunoassay of
human carcinoma solld tumors which signlficantly in
creases location and determlnation of positlve human
carcinoma cells. By removing thls slalic acld steric
hindrance to availability of the KC-4 monoclonal
antibody to bind to the KC-4 antlgen, such cancers can
be detected earller and/or more positively than by pre-
YioUS immunoassay techniques ln which neur~minidase was
no~ usedO The neuraminldase digests the carbohydrate,
sialic acid, that appears to mask the KC-4 antigenic
site and permlts accellerated and/or enhanced detection
of the human carclnoma tumor cells. Applicant has in-
creased in a most productive and useful manner the
ability to detect carcinoma tumor; also applicant bas
inereased the sensitivity to earlier detectlon o~ sueh
cancer by removlng the carbohydrate sterie hindrance of
sialic acld on the KC-4 antigen by neuraminidase treat-
ment as described hereln.
'7~94
Although the method embodying the lnvention has
been descrlbed ln connection wlth immunoassay techni-
ques involving slide staining of pathological samples,
the method ls effective and productive uslng other
techniques such as flow cytometry and microspheres, for
lnstance.
~ . .
~ `
. . .
; .
